DTIL
Precision BioSciences, Inc. NASDAQ Listed Mar 28, 2019$6.81
+4.77%
vs $6.50
Mkt Cap $87.4M
52w Low $3.53
62.0% of range
52w High $8.82
50d MA $7.12
200d MA $5.65
P/E (TTM)
-1.9x
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.3x
ROE
-49.6%
P/FCF
-1.3x
RSI (14)
47.60
ATR (14)
$0.56
Beta
1.09
50d MA
$7.12
200d MA
$5.65
Avg Volume
328.5K
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
302 East Pettigrew Street · Durham, NC 27701 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | BMO | -0.21 | 0.36 | +271.4% | 5.67 | +1.8% | +0.0% | +0.0% | +11.1% | +10.0% | +1.4% | — |
| Nov 3, 2025 | BMO | -0.31 | -1.84 | -493.5% | 7.36 | -1.5% | -9.1% | +0.0% | -1.0% | -2.7% | -4.7% | — |
| Aug 7, 2025 | BMO | -0.09 | -2.13 | -2266.7% | 4.57 | -0.9% | -4.2% | +0.0% | -0.7% | +0.7% | +7.1% | — |
| May 15, 2025 | BMO | -0.43 | -2.21 | -414.0% | 4.55 | +2.0% | +3.5% | +0.0% | -0.4% | +4.1% | -4.7% | — |
| Mar 26, 2025 | BMO | -2.09 | -3.20 | -53.1% | 4.53 | +2.9% | +0.2% | +0.0% | +3.5% | +1.5% | -5.9% | — |
| Nov 4, 2024 | BMO | -0.79 | -2.83 | -258.2% | 8.29 | -1.6% | +2.1% | +0.0% | -0.7% | +0.2% | -0.5% | — |
| Aug 1, 2024 | BMO | -0.77 | 3.46 | +549.4% | 9.57 | +0.6% | -2.6% | +0.0% | -4.4% | -2.4% | -1.3% | — |
| May 13, 2024 | BMO | -0.45 | -0.35 | +22.2% | 11.50 | +4.3% | +1.0% | +0.0% | +4.0% | -0.9% | +3.5% | — |
| Mar 27, 2024 | BMO | 3.00 | -3.35 | -211.7% | 12.98 | +2.0% | +4.5% | +0.0% | +13.3% | -7.6% | +8.7% | — |
| Nov 7, 2023 | BMO | -5.71 | -3.00 | +47.5% | 11.70 | +2.6% | +0.8% | +0.0% | +0.3% | -3.8% | -9.5% | — |
| Aug 4, 2023 | BMO | -6.91 | -3.00 | +56.6% | 16.80 | +1.8% | -5.2% | +0.0% | -0.8% | +2.5% | +0.0% | — |
| May 9, 2023 | BMO | -6.61 | -6.91 | -4.5% | 25.50 | +0.0% | -2.4% | +0.0% | -9.6% | -0.5% | +1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 9 | Oppenheimer | Initiates | Outperform | $20 | $6.77 | $6.97 | +3.0% | +1.3% | -6.0% | -4.3% | -1.1% | +1.8% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.85 | -0.6% | -4.7% | -0.2% | -1.3% | +6.8% | +1.6% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.54 | $4.75 | +4.6% | +3.5% | +1.5% | -5.9% | +4.5% | +0.4% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $4.95 | -0.6% | +0.6% | +7.0% | +1.7% | +3.5% | -9.8% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.35 | +3.9% | +9.7% | +4.2% | +0.7% | -5.1% | -2.8% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $6.80 | +51.1% | +26.7% | +0.7% | -6.3% | -2.2% | -10.3% |
| Jan 10 | BMO Capital | Upgrade | Market Perform → Outperform | — | $4.50 | $6.80 | +51.1% | +26.7% | +0.7% | -6.3% | -2.2% | -10.3% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.27 | $12.15 | -1.0% | +4.5% | +0.6% | +1.6% | +1.0% | -1.7% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.09 | $12.12 | +0.2% | -0.9% | +3.5% | +3.5% | +1.6% | +0.2% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.87 | $11.79 | -8.4% | -10.6% | -6.9% | -9.1% | -0.6% | +5.7% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.98 | $13.24 | +2.0% | +4.5% | +13.3% | -7.6% | +8.7% | -7.1% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.17 | $11.16 | -0.1% | +7.3% | -3.3% | +2.2% | +9.3% | -4.6% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.30 | $13.20 | +7.3% | +0.0% | +3.4% | +1.4% | -8.6% | -3.3% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.90 | $17.64 | +10.9% | -0.9% | -12.4% | +4.3% | -6.2% | +1.1% |
| Jul 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.55 | $17.70 | +0.9% | -3.2% | -0.7% | +2.8% | +0.3% | -5.3% |
| Jul 27 | BTIG | Maintains | Buy → Buy | — | $17.55 | $17.70 | +0.9% | -3.2% | -0.7% | +2.8% | +0.3% | -5.3% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.20 | $25.50 | +1.2% | -11.9% | +3.6% | -2.2% | +8.0% | +0.6% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.67 | $26.34 | -1.2% | +1.1% | -1.2% | -2.0% | -4.6% | +2.4% |
| Mar 13 | BMO Capital | Downgrade | Outperform → Market Perform | — | $27.30 | $28.32 | +3.7% | +2.2% | -4.4% | +1.1% | -1.2% | -2.0% |
| Nov 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $38.10 | $38.40 | +0.8% | +3.9% | +4.5% | +6.5% | -0.7% | +2.1% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.10 | $38.40 | +0.8% | +3.9% | +4.5% | +6.5% | -0.7% | +2.1% |
| Aug 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $52.20 | $53.10 | +1.7% | -7.5% | -5.0% | +7.8% | -1.2% | +23.3% |
| Jun 17 | BMO Capital | Maintains | Outperform → Outperform | — | $34.50 | $34.80 | +0.9% | +9.6% | +10.3% | +7.2% | -2.0% | -0.7% |
| Jun 8 | William Blair | Downgrade | Outperform → Market Perform | — | $62.70 | $64.80 | +3.3% | -12.9% | -20.3% | -6.9% | -10.4% | +0.0% |
| Mar 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $106.20 | $112.20 | +5.6% | -16.4% | +2.4% | +11.6% | -0.9% | -9.0% |
| Sep 9 | Stifel | Maintains | Buy → Buy | — | $378.90 | $381.90 | +0.8% | +1.9% | -1.1% | -0.2% | -4.7% | +2.8% |
| Feb 24 | JonesTrading | Maintains | Buy → Buy | — | $323.10 | $333.00 | +3.1% | +6.9% | -3.3% | +7.5% | +7.6% | -4.4% |
| Dec 6 | JP Morgan | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Apr 2 | Goldman Sachs | Downgrade | Buy → Neutral | — | $158.10 | $157.50 | -0.4% | +5.1% | -15.9% | +21.7% | -1.4% | +3.8% |
| Mar 11 | H.C. Wainwright | Maintains | Buy → Buy | — | $227.10 | $227.10 | +0.0% | -14.3% | -16.5% | +14.0% | -18.3% | +15.2% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $215.70 | $243.60 | +12.9% | +5.3% | -14.3% | -16.5% | +14.0% | -18.3% |
| Mar 5 | Stifel | Maintains | Buy → Buy | — | $243.30 | $247.50 | +1.7% | +2.1% | -3.1% | -10.3% | +5.3% | -14.3% |
| Apr 22 | Goldman Sachs | Maintains | Buy → Buy | — | $365.40 | $386.10 | +5.7% | +10.3% | +1.0% | -5.9% | -2.2% | +1.1% |
| Apr 22 | Jefferies | Maintains | Buy → Buy | — | $365.40 | $386.10 | +5.7% | +10.3% | +1.0% | -5.9% | -2.2% | +1.1% |
| Apr 22 | JP Morgan | Maintains | Overweight → Overweight | — | $365.40 | $386.10 | +5.7% | +10.3% | +1.0% | -5.9% | -2.2% | +1.1% |
| Apr 22 | Barclays | Maintains | Overweight → Overweight | — | $365.40 | $386.10 | +5.7% | +10.3% | +1.0% | -5.9% | -2.2% | +1.1% |
No insider trades available.
8-K · 1.01
!! High
Precision BioSciences, Inc. -- 8-K 1.01: Material Agreement
Precision BioSciences modified its loan agreement terms with lenders, potentially affecting its debt obligations and financial flexibility for operations and research funding.
Jun 16
8-K · 8.01
!! High
Precision BioSciences, Inc. -- 8-K 8.01: Material Event / Announcement
Precision BioSciences' PBGENE-HBV gene-editing therapy achieved a 10-fold reduction in hepatitis B viral DNA in early clinical data, with permanent inactivation of remaining viral replication, supporting advancement toward treating chronic HBV infection.
May 27
8-K · 5.02
!!! Very High
Precision BioSciences, Inc. -- 8-K 5.02: Executive Change
May 26
8-K · 2.02
!! High
Precision BioSciences, Inc. -- 8-K 2.02: Earnings Results
Precision BioSciences reported earnings results via 8-K filing, with complete financial details available in the attached press release exhibit for investors analyzing DTIL/FTRK performance.
May 5
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
DTIL presented Duchenne muscular dystrophy gene therapy data to key opinion leaders, signaling clinical progress that could validate its pipeline and drive future revenue potential.
Mar 17
8-K
Unknown — 8-K Filing
Precision BioSciences (DTIL) executed its 2025 pipeline milestones, suggesting operational competence, but as a clinical-stage biotech with no revenue, investors face binary trial risk before profitability materializes.
Mar 12
8-K · 8.01
!! High
Precision BioSciences, Inc. -- 8-K 8.01: Material Event / Announcement
Precision BioSciences received FDA clearance to proceed with its FUNCTION-DMD Phase 1/2 clinical trial, allowing the company to activate U.S. clinical sites for its gene therapy treatment.
Feb 11
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Meridian Contrarian Fund | 179,140 | $985K | Mar 2026 |
| 2 | Jacob Discovery Fund | 47,089 | $198K | Feb 2026 |
| 3 | Small Cap Core Fund | 7,395 | $41K | Mar 2026 |
| 4 | Guggenheim Active Allocation Fund | 9 | $38 | Feb 2026 |
Valuation
Market Cap
$87.4M
Enterprise Value
-$5.8M
P/E (TTM)
-1.88x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.95x
P/S
2.55x
P/FCF
-1.32x
EV/EBITDA
—
Shares Out
12.8M
Financials (TTM)
Revenue
$34.3M
Net Income
-$46.6M
EBITDA
-$49.4M
Free Cash Flow
-$65.9M
Op Cash Flow
-$65.8M
EPS Basic
$-3.63
EPS Diluted
$-3.63
EPS Forward
$-2.85
Gross Margin
92.0%
Op Margin
-152.2%
Net Margin
-136.0%
Balance Sheet
Total Assets
$154.4M
Total Liab.
$62.2M
Total Equity
$92.2M
Cash
$115.6M
LT Debt
$22.4M
Book Value/Sh
$7.19
Debt/Equity
0.31x
Current Ratio
13.32
Quick Ratio
13.32
Returns & Growth
ROE
-49.6%
ROA
-29.6%
ROIC
-35.5%
Rev Growth YoY
-50.1%
EPS Growth YoY
-445.7%
Price Returns
2W
-14.1%
1M
-2.5%
3M
+66.0%
6M
+28.1%
12M
+44.3%
Technicals
52W High
$8.82
52W Low
$3.53
50d MA
$7.12
200d MA
$5.65
RSI (14)
47.60
ATR (14)
$0.56
Beta
1.09
Avg Volume
328K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$19.00
High
$19.00
Low
$19.00
Median
$19.00
Data updated apr 25, 2026 5:57am
· Source: financialmodelingprep.com